Fingerprint
Dive into the research topics of 'A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Christopher L. Bowlus, Michael R. Galambos, Richard J. Aspinall, Gideon M. Hirschfield, David E.J. Jones, Yvonne Dörffel, Stuart C. Gordon, Stephen A. Harrison, Andreas E. Kremer, Marlyn J. Mayo, Paul J. Thuluvath, Cynthia Levy, Mark G. Swain, Guy W. Neff, David A. Sheridan, Carmen M. Stanca, Christoph P. Berg, Aparna Goel, Mitchell L. Shiffman, John M. Vierling
Research output: Contribution to journal › Article › peer-review
31
Scopus
citations